BR112022007677A2 - L-asparaginase recombinante - Google Patents
L-asparaginase recombinanteInfo
- Publication number
- BR112022007677A2 BR112022007677A2 BR112022007677A BR112022007677A BR112022007677A2 BR 112022007677 A2 BR112022007677 A2 BR 112022007677A2 BR 112022007677 A BR112022007677 A BR 112022007677A BR 112022007677 A BR112022007677 A BR 112022007677A BR 112022007677 A2 BR112022007677 A2 BR 112022007677A2
- Authority
- BR
- Brazil
- Prior art keywords
- asparaginase
- recombinant
- human subject
- administering
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L-ASPARAGINASE RECOMBINANTE. A presente invenção provê composições e métodos para tratar uma doença tratável por depleção de asparagina em um sujeito humano compreendendo administrar a um sujeito humano uma L-asparaginase recombinante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962926201P | 2019-10-25 | 2019-10-25 | |
US202063047222P | 2020-07-01 | 2020-07-01 | |
PCT/EP2020/079972 WO2021078988A1 (en) | 2019-10-25 | 2020-10-23 | Recombinant l-asparaginase |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022007677A2 true BR112022007677A2 (pt) | 2022-10-25 |
Family
ID=73172647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022007677A BR112022007677A2 (pt) | 2019-10-25 | 2020-10-23 | L-asparaginase recombinante |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210308237A1 (pt) |
EP (1) | EP4048303A1 (pt) |
JP (1) | JP2022553399A (pt) |
AU (1) | AU2020371963A1 (pt) |
BR (1) | BR112022007677A2 (pt) |
CA (1) | CA3156066A1 (pt) |
TW (1) | TW202134258A (pt) |
WO (1) | WO2021078988A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
WO2022211829A1 (en) * | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
AR125301A1 (es) * | 2021-04-06 | 2023-07-05 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones de l-asparaginasa |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
SG11202002943PA (en) * | 2017-10-27 | 2020-05-28 | Pfenex Inc | Method for production of recombinant erwinia asparaginase |
MX2020005567A (es) * | 2017-11-30 | 2020-08-20 | Jazz Pharmaceuticals Ireland Ltd | Metodos de tratamiento con asparaginasa. |
-
2020
- 2020-10-23 AU AU2020371963A patent/AU2020371963A1/en active Pending
- 2020-10-23 TW TW109136917A patent/TW202134258A/zh unknown
- 2020-10-23 BR BR112022007677A patent/BR112022007677A2/pt unknown
- 2020-10-23 JP JP2022524024A patent/JP2022553399A/ja active Pending
- 2020-10-23 US US17/078,376 patent/US20210308237A1/en active Pending
- 2020-10-23 EP EP20803449.6A patent/EP4048303A1/en active Pending
- 2020-10-23 WO PCT/EP2020/079972 patent/WO2021078988A1/en active Application Filing
- 2020-10-23 CA CA3156066A patent/CA3156066A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020371963A1 (en) | 2022-05-26 |
TW202134258A (zh) | 2021-09-16 |
US20210308237A1 (en) | 2021-10-07 |
WO2021078988A1 (en) | 2021-04-29 |
CA3156066A1 (en) | 2021-04-29 |
JP2022553399A (ja) | 2022-12-22 |
EP4048303A1 (en) | 2022-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022007677A2 (pt) | L-asparaginase recombinante | |
CL2022003763A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
CO2018003168A2 (es) | Moduladores de la expresión de kras | |
BR112017017286A2 (pt) | protease de cisteína | |
BR112017026739A2 (pt) | compostos para uso no tratamento de distúrbios neuromusculares | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
BR112017017284A2 (pt) | protease de cisteína | |
BR112017011900A2 (pt) | tratamento de ataques com fosfatase alcalina recombinante | |
BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
BR112012012918A2 (pt) | agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes. | |
BR112012011331A2 (pt) | uso de receptor similar à toll agonista para tratamento de câncer | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
BR112021018687A2 (pt) | Combinação de dose fixa de canabinoides e cogumelos medicinais para prevenção e tratamento de câncer, doenças inflamatórias ou inflamatórias imunomediadas | |
BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
BR112014006473A2 (pt) | composição e método para tratamento de uma doença autoimune | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al |